Technical Analysis for IKNA - Ikena Oncology, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 50 DMA Resistance | Bearish | -4.44% | |
| Crossed Above 20 DMA | Bullish | -4.44% | |
| MACD Bullish Signal Line Cross | Bullish | -4.44% | |
| Pocket Pivot | Bullish Swing Setup | -4.44% | |
| Bollinger Band Squeeze | Range Contraction | -4.44% | |
| 20 DMA Resistance | Bearish | -0.77% | |
| Bollinger Band Squeeze | Range Contraction | -0.77% |
| Alert | Time |
|---|---|
| Down 5% | about 6 hours ago |
| Fell Below Previous Day's Low | about 6 hours ago |
| Fell Below 10 DMA | about 6 hours ago |
| Possible Inside Day | about 8 hours ago |
| 10 DMA Support | about 9 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.6399 |
| 52 Week Low | 1.02 |
| Average Volume | 445,393 |
| 200-Day Moving Average | 2.86 |
| 50-Day Moving Average | 1.40 |
| 20-Day Moving Average | 1.33 |
| 10-Day Moving Average | 1.30 |
| Average True Range | 0.11 |
| RSI (14) | 44.44 |
| ADX | 16.13 |
| +DI | 15.44 |
| -DI | 17.05 |
| Chandelier Exit (Long, 3 ATRs) | 1.17 |
| Chandelier Exit (Short, 3 ATRs) | 1.54 |
| Upper Bollinger Bands | 1.42 |
| Lower Bollinger Band | 1.23 |
| Percent B (%b) | 0.31 |
| BandWidth | 14.43 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.04 |
| MACD Histogram | 0.0045 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.47 | ||||
| Resistance 3 (R3) | 1.48 | 1.44 | 1.44 | ||
| Resistance 2 (R2) | 1.44 | 1.39 | 1.43 | 1.43 | |
| Resistance 1 (R1) | 1.36 | 1.36 | 1.34 | 1.35 | 1.42 |
| Pivot Point | 1.32 | 1.32 | 1.31 | 1.31 | 1.32 |
| Support 1 (S1) | 1.24 | 1.27 | 1.22 | 1.23 | 1.16 |
| Support 2 (S2) | 1.20 | 1.24 | 1.19 | 1.15 | |
| Support 3 (S3) | 1.12 | 1.20 | 1.14 | ||
| Support 4 (S4) | 1.11 |
